To amend Public Health Service Act to require community health centers to provide behavioral and mental health and substance use disorder services, and for other purposes.

HR8201 was introduced on April 6, 2026 by Rep. Susie Lee (D-NV-3) and referred to the House Committee on Energy and Commerce — the first of many legislative steps required for passage. As an 'authorization' bill, it sets policy and spending ceilings but does not allocate actual funds. The $700 million per year for FY2027-2031 would require a separate appropriations bill to become real spending. The bill has no companion bill in the Senate and no cosponsors listed, indicating limited early momentum. The money trail: Section 1(b) amends the Affordable Care Act to transfer funds from the Secretary of HHS to community health centers for enhanced behavioral health and SUD services. This is a 'transfer authorization' — it directs HHS to move existing money within its budget, not new deficit spending. The actual source of funds would depend on appropriators. The primary economic mechanism is a regulatory mandate: FQHCs must now include behavioral health and SUD services as 'required primary health services' to qualify for federal grants under Section 330 of the Public Health Service Act. Structural winners are healthcare service providers and insurers with FQHC exposure. Molina Healthcare (MOH), Centene (CNC), and other Medicaid-focused MCOs could benefit from reduced ER utilization if FQHCs build behavioral health capacity. Pharmacy benefit managers and drug distributors (CVS, CI) may see marginal volume increases in psychotropic medications and MAT drugs (buprenorphine, naltrexone) prescribed at FQHCs. Vaccines and therapeutic manufacturers (PFE, JNJ, MRNA, NVAX) are tangential — the bill does not change vaccine requirements. The competitive landscape favors large FQHC networks like Community Health Center, Inc. (private) and other grantee organizations over for-profit providers. No publicly traded company has FQHC operation as its primary business — the impact is indirect through insurance contracts and pharmaceutical procurement. Timeline: The bill must pass the Energy and Commerce Committee, then the full House, then find a Senate companion, pass the Senate, and reconcile differences before reaching the President's desk. The earliest this could become law is late 2026 or 2027. The current 119th Congress session runs through January 2027 — this bill faces a tight calendar given the late introduction date.